A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
Dimos D Mitsikostas, Triantafyllos Doskas, Stylianos Gkatzonis, Nikolaos Fakas, Maria Maltezou, Dimitrios Papadopoulos, Rania Gourgioti, Panayiotis Mitsias, Dimos D Mitsikostas, Triantafyllos Doskas, Stylianos Gkatzonis, Nikolaos Fakas, Maria Maltezou, Dimitrios Papadopoulos, Rania Gourgioti, Panayiotis Mitsias
Abstract
Introduction: The efficacy of prolonged-release fampridine (PR-FAM) may extend in multiple sclerosis (MS) beyond walking ability. The objective of this study was to evaluate the effect of PR-FAM treatment on cognition, fatigue, depression, and quality of life (QoL) in adult patients with MS in a real-world setting.
Methods: FAMILY was a multi-center, prospective, observational, real-world cohort study of MS patients receiving PR-FAM in the outpatient setting. Patients were treated as per PR-FAM's local prescribing information for 6 months. Standardized protocols and questionnaires were used to evaluate changes in cognition (PASAT; Paced Auditory Serial Addition Test), fatigue (MFIS; Modified Fatigue Impact Scale), depression (BDI-II; Beck Depression Inventory-II) and QoL (MusiQoL; MS International Quality-of-Life questionnaire, MSIS-29; Multiple Sclerosis Impact Scale: PHYS and PSYCH subscales) at 3 and 6 months compared to baseline.
Results: In total, 102 eligible patients from 8 sites in Greece were analysed, of whom 92 completed the study and 10 discontinued. At 6 months, PR-FAM treatment resulted in improvements from baseline in PASAT-3'' (p = 0.044), MFIS (p < 0.001), BDI-II (p < 0.001), MusiQoL (p < 0.001) and MSIS-29-PHYS (p = 0.012) and MSIS-PSYCH (p < 0.001). A positive effect was evident already at 3 months in PASAT-3'' (ns), MFIS (p = 0.020), BDI-II (p = 0.034), MusiQoL (p = 0.001), MSIS-29-PHYS (ns) and MSIS-29-PSYCH (p < 0.001).
Conclusions: This observational study provides new data to the current literature in support of PR-FAM's positive effects in cognition, fatigue, depression, and QoL in a large, heterogeneous group of Greek MS patients in the real-world setting.
Trial registration: ClinicalTrials.gov identifier, NCT03164018.
Keywords: Cognition; Depression; Fatigue; Multiple sclerosis; Neurology; PR-FAM; QoL; Walking ability.
Figures
References
- Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, et al. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther. Adv. Neurol. Disord. 2018;11:1–8.
- Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J. Neurol. Sci. 2009;277(S1):S37–41.
- Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: The impact of depression, fatigue and disability. Mult Scler. 2001;7:340–344.
- Rodriguez-Leal FA, Haase R, Akgün K, Eisele J, Proschmann U, Schultheiss T, et al. Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. Ther Adv Chronic Dis. 2019;10:1–11.
- Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367–368.
- Lerdal A, Gulowsen Celius E, Krupp L, Dahl AA. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14(12):1338–1343.
- Braley TJ, Chervin RD. Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment. Sleep [Internet]. 2010;33:1061–7. Available from: 10.1093/sleep/33.8.1061
- Tur C. Fatigue Management in Multiple Sclerosis. Curr. Treat. Options Neurol. 2016;18:26.
- Rosti E, Hämäläinen P, Koivisto K, Hokkanen L. PASAT in detecting cognitive impairment in relapsing-remitting MS. Appl Neuropsychol. 2007;14(2):101–112.
- Moccia M, Lanzillo R, Palladino R, Chang KCM, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22(5):659–667.
- Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis [Internet]. Int. Rev. Psychiatry. Taylor and Francis Ltd; 2017;29(5):463–72. Available from: 10.1080/09540261.2017.1322555.
- Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. Neurology. 2019;93:1–8.
- Ysrraelit MC, Fiol MP, Gaitán MI, Correale J. Quality of life assessment in multiple sclerosis: Different perception between patients and neurologists. Front Neurol. 2018;8:729.
- Dunn J, Blight A. Dalfampridine: A brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr. Med. Res. Opin. 2011;27(7):1415–1423.
- EMA. Assessment Report; Fampyra [Internet]. 2011. Available from:
- EMA. Assessment Report; Fampyra [Internet]. 2017. Available from:
- Korsen M, Kunz R, Schminke U, Runge U, Kohlmann T, Dressel A. Dalfampridine effects on cognition, fatigue, and dexterity. Brain Behav. 2017;7(1):e0059.
- Broicher SD, Filli L, Geisseler O, Germann N, Zörner B, Brugger P, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol. 2018;265(5):1016–25.
- Triche EW, Ruiz JA, Olson KM, Lo AC. Changes in cognitive processing speed, mood, and fatigue in an observational study of persons with multiple sclerosis treated with dalfampridine-ER. Clin Neuropharmacol. 2016;39(2):73–80.
- Jacques F, Schembri A, Nativ A, Paquette C, Kalinowski P. Prolonged-release fampridine as adjunct therapy to active motor training in ms patients: a pilot, double-blind, randomized, placebo-controlled study. Mult Scler J Exp Transl Clin. 2018;4(1):2055217318761168.
- Rodriguez-Leal FA, Haase R, Thomas K, Eisele JC, Proschmann U, Schultheiss T, et al. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? Mult Scler J. 2018;24(10):1337–1346.
- Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, et al. Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33(1):61–79.
- Jensen HB, Nielsen JL, Ravnborg M, Dalgas U, Aagaard P, Stenager E. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Mult Scler Relat Disord. 2016;10:137–144.
- Morrow SA, Rosehart H, Johnson AM. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord. 2017;11:4–9.
- Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al. Fatigue in progressive multiple sclerosis: Results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7(6):354–8.
- Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, et al. Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci. 2014;337(1–2):18–24.
- Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35–40.
- Bakirtzis C, Konstantinopoulou E, Langdon DW, Grigoriadou E, Minti F, Nikolaidis I, et al. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS : The IGNITE study. J Neurol Sci. 2018;395:106–112.
- Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262(8):1936–45.
- Jensen HB, Ravnborg M, Mamoei S, Dalgas U, Stenager E. Changes in cognition, arm function and lower body function after slow-release fampridine treatment. Mult Scler J. 2014;20:1872–1880.
- Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K, et al. Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Mult Scler J. 2020;26(1):91–98.
- Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33(11):1087–1099.
- Fischer JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999;5(4):244–250.
- Fischer JS, Jak AJ, Judith Kniker ME, Richard Rudick MA, Cutter G, Ellison G, et al. Administration and scoring manual manual prepared by administration and scoring manual. 2001
- Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12) Neurology. 2003;60(1):31–6.
- Bakalidou D, Voumvourakis K, Tsourti Z, Papageorgiou E, Poulios A, Giannopoulos S. Validity and reliability of the Greek version of the Modified Fatigue Impact Scale in multiple sclerosis patients. Int J Rehabil Res. 2014;37(3):271–276.
- Miskovic A, Ehrlich-Jones L. Measurement characteristics and clinical utility of the modified fatigue impact scale in individuals with multiple sclerosis. Arch Phys Med Rehabil. 2018;97(7):1219–1220.
- Giannakou M, Roussi P, Kosmides ME, Kiosseoglou G, Adamopoulou A, Garyfallos G. Adaptation of the beck depression inventory-II to greek population. Hell J Psychol. 2013;10(2):120–146.
- Watson TM, Ford E, Worthington E, Lincoln NB. Validation of mood measures for people with multiple sclerosis. Int J MS Care. 2014;16(2):105–109.
- Triantafyllou N, Triantafillou A, Tsivgoulis G. Validity and reliability of the greek version of the multiple sclerosis international quality-of-life questionnaire. J Clin Neurol. 2009;5(4):173–177.
- Baumstarck K, Butzkueven H, Fernández O, Flachenecker P, Stecchi S, Idiman E, et al. Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. Health Qual Life Outcomes. 2013;11:127.
- Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, et al. The physical and psychological impact of multiple sclerosis using the MSIS-29 via the web portal of the UK MS register. PLoS One. 2013;8(1):e55422.
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
- Ozakbas S, Yigit P, Cinar B. The effect of fampridine treatment on cognition: two year prospective study. Mult Scler J. 2017;23:412.
- De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, et al. Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019;9:1–14.
- Foschi M, Lugaresi A. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? Expert Opin Pharmacother. 2019;20(11):1309–1320.
- Sumowski JF, Muhlert N. Dalfampridine improves slowed processing speed in MS: picking up the pace. Neurology. 2019;93(8):325.
- Rosti E, Hämäläinen P, Koivisto K, Hokkanen L. One-year follow-up study of relapsing-remitting MS patients’ cognitive performances: paced auditory serial addition test’s susceptibility to change. J Int Neuropsychol Soc [Internet]. 2007;13:791–8. Available from:
- Sagawa Y, Magnin E, Paillot L, Moulin T, Decavel P. Fampridine and quality of life in individuals with multiple sclerosis. Springerplus. 2016;5(1):1070.
- Khan F, Amatya B, Galea M. Management of fatigue in persons with multiple sclerosis. Front Neurol [Internet]. Frontiers Research Foundation; 2014;5:177. Available from:
- Gasperini C, Hupperts R, Lycke J, Short C, McNeill M, Zhong J, et al. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. J Neurol Sci. 2016;370:123–131. doi: 10.1016/j.jns.2016.08.052.
- Nagels G, Macdonell R, Soelberg Sorensen P, Pozzilli C, Laplaud D, de Jong B, et al. Long-Term Prolonged-Release Fampridine Treatment and Health-Related Quality of Life Outcomes: Interim Results of the Enable Study. Value Heal. 2013;16(7):627.
- Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;16:1509–1517.
- Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies A clinical point of view. Approaches and methodologies. Pulm. Pharmacol. Ther. 2014;27(2):129–138. doi: 10.1016/j.pupt.2014.01.005.
- Mahajan R. Real world data: Additional source for making clinical decisions. Int J Appl Basic Med Res. 2015;5(2):82. doi: 10.4103/2229-516X.157148.
Source: PubMed